Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27360252 | 0.93 | TRPA1 (0.58) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL5833581 | 0.90 | TRPA1 (0.56) | MAOAHTR2ASMN1; SMN2TRPA1GRIK1 | |
| SCHEMBL6680790 | 0.88 | HTR2A (0.54) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL3715946 | 0.86 | MAOA (0.52) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL3715878 | 0.86 | MAOA (0.52) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL2921490 | 0.86 | TRPA1 (0.53) | MAOASMN1; SMN2TRPA1GRIK1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL8852295 | 0.84 | TRPA1 (0.51) | SMN1; SMN2TRPA1GRIK1MAOB | |
| SCHEMBL20019603 | 0.82 | TDP1 (0.52) | MAOASMN1; SMN2TRPA1GRIK1SIGMAR1 | |
| SCHEMBL7285852 | 0.82 | TDP1 (0.52) | MAOASMN1; SMN2TRPA1GRIK1HTR3A | |
| SCHEMBL19682101 | 0.82 | TRPA1 (0.67) | MAOATRPA1MAOBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289514-B1 | USE OF SUBSTITUTED 1-AMINO-5-PHENYLPENTANE-3-OL AND/OR 1-AMINO-6-PHENYLHEXANE-3-OL COMPOUNDS AS MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2004-11-03 | — | — | EP | claimed |
| US-6784175-B2 | WITH AN N-METHYL-D-ASPARTATE (NMDA) ANTAGONISTIC EFFECT | GRUENENTHAL GMBH (DE) | 2004-08-31 | — | — | US | claimed |
| US-20030181450-A1 | Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments | GRUENENTHAL GMBH (DE) | 2003-09-25 | — | — | US | claimed |
| EP-1289514-B1 | USE OF SUBSTITUTED 1-AMINO-5-PHENYLPENTANE-3-OL AND/OR 1-AMINO-6-PHENYLHEXANE-3-OL COMPOUNDS AS MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2004-11-03 | — | — | EP | disclosed |
| EP-1289514-B1 | USE OF SUBSTITUTED 1-AMINO-5-PHENYLPENTANE-3-OL AND/OR 1-AMINO-6-PHENYLHEXANE-3-OL COMPOUNDS AS MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2004-11-03 | — | — | EP | disclosed |
| US-6784175-B2 | WITH AN N-METHYL-D-ASPARTATE (NMDA) ANTAGONISTIC EFFECT | GRUENENTHAL GMBH (DE) | 2004-08-31 | — | — | US | disclosed |
| US-6784175-B2 | WITH AN N-METHYL-D-ASPARTATE (NMDA) ANTAGONISTIC EFFECT | GRUENENTHAL GMBH (DE) | 2004-08-31 | — | — | US | disclosed |
| US-6784175-B2 | WITH AN N-METHYL-D-ASPARTATE (NMDA) ANTAGONISTIC EFFECT | GRUENENTHAL GMBH (DE) | 2004-08-31 | — | — | US | disclosed |
| US-20030181450-A1 | Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments | GRUENENTHAL GMBH (DE) | 2003-09-25 | — | — | US | disclosed |
| US-20030181450-A1 | Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments | GRUENENTHAL GMBH (DE) | 2003-09-25 | — | — | US | disclosed |
| US-20030181450-A1 | Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments | GRUENENTHAL GMBH (DE) | 2003-09-25 | — | — | US | disclosed |
| EP-1289514-A1 | USE OF SUBSTITUTED 1-AMINO-5-PHENYLPENTANE-3-OL AND/OR 1-AMINO-6-PHENYLHEXANE-3-OL COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2003-03-12 | — | — | EP | disclosed |
| EP-1289514-A1 | USE OF SUBSTITUTED 1-AMINO-5-PHENYLPENTANE-3-OL AND/OR 1-AMINO-6-PHENYLHEXANE-3-OL COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001089505-A1 | USE OF SUBSTITUTED 1-AMINO-5-PHENYLPENTANE-3-OL AND/OR 1-AMINO-6-PHENYLHEXANE-3-OL COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001089505-A1 | USE OF SUBSTITUTED 1-AMINO-5-PHENYLPENTANE-3-OL AND/OR 1-AMINO-6-PHENYLHEXANE-3-OL COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181450-A1 | Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments | GRIN3A, GRIN1, GRIN3B | MAOA 1642/4885HTR2A 270/4885CYP2A6 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.